These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Chylothorax as a complication of Waldenström macroglobulinaemia with a patient's perspective. Gary P, Gianniosis M, Ryu J, Flynn S. BMJ Case Rep; 2021 May 07; 14(5):. PubMed ID: 33962927 [Abstract] [Full Text] [Related]
13. MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. Gustine JN, Meid K, Hunter ZR, Xu L, Treon SP, Castillo JJ. Br J Haematol; 2018 Feb 07; 180(4):578-581. PubMed ID: 27748515 [No Abstract] [Full Text] [Related]
14. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM. Intern Med J; 2017 Jan 07; 47(1):35-49. PubMed ID: 28076910 [Abstract] [Full Text] [Related]
15. Ibrutinib for the treatment of Waldenström macroglobulinemia. Chakraborty R, Kapoor P, Ansell SM, Gertz MA. Expert Rev Hematol; 2015 Oct 07; 8(5):569-79. PubMed ID: 26138997 [Abstract] [Full Text] [Related]